[Form 4] Tecogen Inc. Insider Trading Activity

Rhea-AI Filing Summary

Tecogen Inc. (TGEN) Form 4: On 07/24/2025, director Angelina Galiteva was granted a non-qualified stock option for 25,000 shares of common stock at an exercise price of $8.35. The option vests 25 % annually and expires on 07/25/2035. No shares were sold or otherwise disposed of in this filing. Following the grant, Galiteva’s total derivative holdings stand at 225,000 option-linked shares. The filing, dated 07/28/2025, shows the transaction was made in a direct ownership capacity; there is no indication of indirect ownership or group filing. No non-derivative transactions were reported.

Positive

• No insider sales; the director increased potential ownership via options, which can strengthen alignment with shareholder interests.

Negative

• Potential dilution of approximately 0.5 % if options are exercised, though impact is minimal given company size.

Insights

Securities Analyst

TL;DR – Routine option grant; neutral impact, but modestly aligns director incentives with shareholders.

The reported 25,000-share option represents roughly 0.5 % of Tecogen’s 4.6 million shares outstanding, a minor potential dilution. An $8.35 strike price suggests the award is performance-contingent: value accrues only if management delivers upside. The 10-year term and 25 % annual vesting follow typical governance practices. No insider selling occurred, so the transaction does not signal negative sentiment. Overall, the filing is administrative and does not materially shift ownership or capital structure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

GALITEVA ANGELINA

(Last) (First) (Middle)

8845 WREN AVENUE

(Street)

FOUNTAIN VALLEY CA 92708

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TECOGEN INC. [ TGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.35	07/24/2025		A		25,000		07/24/2026(1)	07/25/2035	Common Stock	25,000	$8.35	225,000	D

Explanation of Responses:

1. Vests 25% per year

Remarks:

	/s/ Angelina Galiteva	07/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Tecogen (TGEN) report in the latest Form 4?

Director Angelina Galiteva received a stock option for 25,000 shares at a strike price of $8.35.

When was the Tecogen option grant made and when does it expire?

Granted on 07/24/2025, the option expires on 07/25/2035.

What is the vesting schedule for the new Tecogen stock option?

The option vests 25 % per year, fully vesting after four years.

How many derivative securities does the director own after this transaction?

Galiteva now holds 225,000 option-based shares in total.

Were any shares of Tecogen sold in this Form 4 filing?

No; the filing reports only an option grant, with zero disposals.